SCHEMBL1452263

SCHEMBL1452263

CC1=Cc2c(Br)cc(-c3cccs3)cc2C1CC1C(C)=Cc2c(Br)cc(-c3cccs3)cc21

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT6 Q96LA8 1/20 0.33
LTA4H P09960 1/20 0.33
KCNH2 Q12809 1/20 0.32
MEN1 O00255 1/20 0.31
USP2 O75604 1/20 0.31
ALDH1A1 P00352 1/20 0.31
LMNA P02545 1/20 0.31
POLB P06746 1/20 0.31
MAPT P10636 1/20 0.31
ALOX15 P16050 1/20 0.31
ALOX12 P18054 1/20 0.31
MAPK1 P28482 1/20 0.31
KMT2A Q03164 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
HSD17B10 Q99714 1/20 0.31
PTPN1 P18031 1/20 0.31
PDGFRB P09619 1/20 0.30
PDGFRA P16234 1/20 0.30
CYP17A1 P05093 1/20 0.30
CYP11B1 P15538 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1453960 0.92 PRMT6 (0.33) PRMT6LTA4HKCNH2MEN1USP2
SCHEMBL4653367 0.82 KCNH2 (0.32) PRMT6KCNH2MEN1USP2ALDH1A1
SCHEMBL1452759 0.81 SMN1; SMN2 (0.33) KCNH2MEN1USP2ALDH1A1LMNA
SCHEMBL1453866 0.81 KCNH2 (0.34) PRMT6KCNH2MEN1USP2ALDH1A1
SCHEMBL1452192 0.79 CRHBP (0.40)
SCHEMBL1453476 0.77 LTA4H (0.33) LTA4HALDH1A1MAPTMAPK1SMN1; SMN2
SCHEMBL1453561 0.77 LMNA (0.31) LMNAMAPT
SCHEMBL1454019 0.77 KCNH2 (0.41) PRMT6LTA4HKCNH2CYP17A1CYP11B1
SCHEMBL1451748 0.72 CHRNB4 (0.34) MEN1ALDH1A1MAPTKMT2A
SCHEMBL1452740 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7910783-B2 Preparation of substituted bridged indenyl and related ligands EXXONMOBIL CHEMICAL PATENTS INC. (US) 2011-03-22 US disclosed
EP-1971621-A1 PREPARATION OF SUBSTITUTED BRIDGED INDENYL AND RELATED LIGANDS ExxonMobil Chemical Patents Inc. (US) 2008-09-24 EP disclosed
WO-2007070045-A1 PREPARATION OF SUBSTITUTED BRIDGED INDENYL AND RELATED LIGANDS EXXONMOBIL CHEMICAL PATENTS, INC. (US) 2007-06-21 WO disclosed
US-20070135596-A1 Preparation of substituted bridged indenyl and related ligands EXXONMOBIL CHEMICAL PATENTS INC. 2007-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135596-A1 Preparation of substituted bridged indenyl and related ligands SP1, TTL, TTLL12 PRMT6 1610/4885LTA4H 4290/4885KCNH2 1293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.